Stockscreener 앱 받기
5.01
11.58%
0.52
시간 외 거래:
5.07
0.06
+1.20%
전일 마감가:
$4.49
열려 있는:
$4.5
하루 거래량:
4.66M
Relative Volume:
0.95
시가총액:
$3.49B
수익:
$1.31M
순이익/손실:
$-597.65M
주가수익비율:
-4.3947
EPS:
-1.14
순현금흐름:
$-425.62M
1주 성능:
-8.07%
1개월 성능:
+41.13%
6개월 성능:
-34.51%
1년 성능:
+21.01%
1일 변동 폭
$4.45
$5.04
1주일 범위
$4.43
$5.44
52주 변동 폭
$3.10
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
IBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IBRX | 5.01 | 3.49B | 1.31M | -597.65M | -425.62M | -1.14 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 개시 | Jefferies | Buy |
Immunitybio Inc 주식(IBRX)의 최신 뉴스
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
ImmunityBio Reports Third-Quarter 2024 Financial Results - The Bakersfield Californian
ImmunityBio Q3 Revenue Soars 500% as ANKTIVA Sales Surge; Expands Insurance Coverage | IBRX Stock News - StockTitan
(IBRX) Technical Pivots with Risk Controls - Stock Traders Daily
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3%Should You Sell? - MarketBeat
Why ImmunityBio Stock Is Trading Higher Thursday - MSN
Commit To Buy ImmunityBio At $4, Earn 25% Using Options - Nasdaq
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes - Law360
Penny Stock Trades: Joby Aviation and ImmunityBio - Baystreet.ca
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6%Here's Why - MarketBeat
(IBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - TipRanks
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025 - Seeking Alpha
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume – Still a Buy? - Defense World
ImmunityBio Stock Heats Up, Catches Retail's Eye On Cancer Drug Trial Progress And Analyst’s Bullish Call - Barchart
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
ImmunityBio stock jumps after trial update (IBRX:NASDAQ) - Seeking Alpha
Stock Traders Buy High Volume of ImmunityBio Call Options (NASDAQ:IBRX) - MarketBeat
EF Hutton sees over 600% upside in biotech small cap ImmunityBio - Kursiv Media
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
ImmunityBio (IBRX) Stock Extends Pre-Hour Rally Following Clinical Trial News - Stocks Telegraph
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL - Yahoo! Voices
ImmunityBio begins dosing in Phase 1 trial of CAR-NK therapy for relapsed NHL - World Pharmaceutical Frontiers
ImmunityBio (NASDAQ:IBRX) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I - Defense World
ImmunityBio (NASDAQ:IBRX) Trading 7.8% HigherHere's What Happened - MarketBeat
ImmunityBio Stock Could Rocket 800%, Analyst Says - Barron's
This Biotech Stock Could Rocket 800%, Analyst Says - MSN
ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL - TipRanks
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma - Business Wire
ImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I - MarketBeat
800% Upside For This Biotech StockAnalyst Initiates Coverage On Bladder Cancer Focused ImmunityBio - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's What Happened - MarketBeat
EF Hutton sets stock target with buy rating for ImmunityBio, cites cancer therapy - Investing.com
Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact L - GuruFocus.com
Layoff Tracker: Takeda Cuts More Employees, Total Exceeds 1,300 in 2024 - BioSpace
ImmunityBio to Participate in the Jefferies London Healthcare Conference - BioSpace
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? - AOL
Immunitybio Inc (IBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):